Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT02036970

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
  • Biogen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02036970
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Germany (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02036970. Randomized; double masking; primary purpose treatment. Start 2014-05-31 (actual); primary completion 2018-01-19 (actual). Results posted on 2021-07-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
Condition
Pulmonary Arterial Hypertension
Condition
Interstitial Lung Disease
Condition
Idiopathic Interstitial Pneumonia
Condition
Idiopathic Pulmonary Fibrosis
Condition
Sarcoidosis
Condition
Respiratory Bronchiolitis Associated Interstitial Lung Disease
Condition
Desquamative Interstitial Pneumonia
Condition
Cryptogenic Organizing Pneumonia
Condition
Acute Interstitial Pneumonitis
Condition
Idiopathic Lymphoid Interstitial Pneumonia
Condition
Idiopathic Pleuroparenchymal Fibroelastosis
Intervention (Drug)
Bardoxolone methyl
Intervention (Drug)
Placebo
Lead sponsor
Biogen (class: industry)

Record details

Record id
cardio:ct-nct02036970
Content hash
5a4c3b20db7ac6f1aac76c385a7d31ca198d19cc6461cdf14faf37b205c5764c